Pacira BioSciences
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Pacira BioSciences (PCRX) | 1.46B | 39.23 | 2.05 | 0.00% |
| Takeda Pharmaceutical (TAK) | 69.76B | 311.00 | 1.50 | 1.44% |
| Teva Pharmaceutical Industries (TEVA) | 45.77B | 91.23 | 5.74 | 0.00% |
| Haleon (HLN) | 39.76B | 19.14 | 1.85 | 2.09% |
| Zoetis (ZTS) | 32.14B | 13.34 | 9.73 | 2.64% |
| United Therapeutics (UTHR) | 23.63B | 20.94 | 3.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 16.5% below Morningstar's fair value estimate.
Fair value
Pacira BioSciences Inc earns a 5-star quantitative star rating, illustrating our stance that this share class offers a compelling opportunity for investors. The stock currently trades at a 14% discount to our quantitative fair value estimate of $42.49 per share, which is reinforced by this estimate's low uncertainty rating.
The firm's profitability strengthens our valuation estimate. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. Reflecting the firm's profitability is its earnings yield of 5.2%, which ranks in the top 45% globally. This suggests that it is generating substantial earnings relative to its share price, which contributes to our view that shares are cheap.
The company's valuation metrics are an additional encouraging factor. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's price to cash ratio of 4.9, for example, sits in the bottom 45% globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. This characteristic further promotes our favorable price/fair value ratio.
Economic moat
This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
By Quantitative Equity Report
Quote time 2026-11-19 19:54:59 · For reference only, not investment advice and not tailored to your situation.
Pacira BioSciences discussion 0 comments